These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
741 related articles for article (PubMed ID: 25465337)
1. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337 [TBL] [Abstract][Full Text] [Related]
2. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753 [TBL] [Abstract][Full Text] [Related]
3. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057 [TBL] [Abstract][Full Text] [Related]
4. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Murphy AB; Carbunaru S; Nettey OS; Gornbein C; Dixon MA; Macias V; Sharifi R; Kittles RA; Yang X; Kajdacsy-Balla A; Gann P Urology; 2020 Aug; 142():166-173. PubMed ID: 32277993 [TBL] [Abstract][Full Text] [Related]
5. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. Cullen J; Lynch JA; Klein EA; Van Den Eeden SK; Carroll PR; Mohler JL; Knezevic D; Farrington TA; Lu R J Urol; 2021 Apr; 205(4):1047-1054. PubMed ID: 33493001 [TBL] [Abstract][Full Text] [Related]
6. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214 [TBL] [Abstract][Full Text] [Related]
7. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. Helfand BT; Paterakos M; Wang CH; Talaty P; Abran J; Bennett J; Hall DW; Lehman A; Aboushwareb T PLoS One; 2022; 17(9):e0273782. PubMed ID: 36048818 [TBL] [Abstract][Full Text] [Related]
8. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Faisal FA; Sundi D; Cooper JL; Humphreys EB; Partin AW; Han M; Ross AE; Schaeffer EM Urology; 2014 Dec; 84(6):1434-41. PubMed ID: 25432835 [TBL] [Abstract][Full Text] [Related]
9. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864 [TBL] [Abstract][Full Text] [Related]
10. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. Cullen J; Kuo HC; Shan J; Lu R; Aboushwareb T; Van Den Eeden SK Urology; 2020 Sep; 143():103-111. PubMed ID: 32525077 [TBL] [Abstract][Full Text] [Related]
11. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079 [TBL] [Abstract][Full Text] [Related]
13. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959 [TBL] [Abstract][Full Text] [Related]
14. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440 [TBL] [Abstract][Full Text] [Related]
15. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405 [TBL] [Abstract][Full Text] [Related]
16. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204 [TBL] [Abstract][Full Text] [Related]
17. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118 [TBL] [Abstract][Full Text] [Related]
18. Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men. Epstein M; Syed K; Danella J; Ginzburg S; Belkoff L; Tomaszewski J; Trabulsi E; Singer EA; Jacobs BL; Raman JD; Guzzo TJ; Uzzo R; Reese AC Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):257-263. PubMed ID: 37821578 [TBL] [Abstract][Full Text] [Related]